echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > "Type 1 Diabetes" global circulation data released!

    "Type 1 Diabetes" global circulation data released!

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Yimaitong compiles and organizes, please do not reprint without authorization
    .

    Introduction: When asked about the difference between type 1 diabetes and type 2 diabetes, "absolute beta cell deficiency", "lifelong insulin dependence", and "less than 5% of the total number of diabetic people" will be the answers of many people, but the number of 5% is not It cannot accurately describe the prevalence of type 1 diabetes, but it conceals the huge differences between different countries/regions, income levels, and age groups
    .

    On October 2nd, a worldwide research on type 1 diabetes was published in the journal Diabetologia (impact factor: 10.
    122), which filled the gaps in the understanding of type 1 diabetes
    .

    Type 1 diabetes that has been "neglected" is behind the shortened life span of more than 10 years.
    Diabetes is one of the four non-communicable diseases recognized by the WHO
    .

    Although it includes type 1 diabetes and type 2 diabetes, it has received more attention due to its large proportion of type 2 diabetes, the risk factors for various diseases and the greater burden it brings
    .

    Previous studies have estimated that type 1 diabetes accounts for about 5%-10% of overall diabetes, but this statement is usually based on data from the Nordic population (the incidence and prevalence of type 1 diabetes in this population is usually the highest in the world Of)
    .

    And the current data on the incidence and prevalence of type 1 diabetes is limited (especially for the adult population)
    .

    In short, compared with type 2 diabetes, type 1 diabetes has been overlooked to a certain extent
    .

    The emergence of insulin has saved hundreds of millions of patients with type 1 diabetes, but it does not mean that the health problems have been completely resolved
    .

    Research based on a large sample of European populations shows that the life expectancy of type 1 diabetes patients is compared with that of the general population: ➤Diagnosed at the age of 20: Reduced by about 11 years and 13 years for men and women; ➤Diagnosed before the age of 10: Reduced by about 14 years for men and women, respectively Years and 18 years
    .

    It is reasonable to speculate that patients living in low-income countries may be worse off due to the lack of access to the same medical care support
    .

    Type 1 diabetes accounts for about 2% of the total cases, and there are huge differences between countries, less than 1% in China.
    The study analyzed the incidence/prevalence of type 1 diabetes in all age groups in the world in 2017, showing that type 1 diabetes is more important than diabetes worldwide The proportion of total cases ranges from less than 1% in some Pacific countries to more than 15% in Nordic countries, and there are huge differences between different countries/regions
    .

    In addition, although the proportion of patients with onset age <15 years old is the largest (42%), there are still up to 35.
    0% and 17.
    4% of type 1 diabetes patients who have the onset of type 1 diabetes between the ages of 15-39 and 40-64
    .

    As far as the status quo is concerned, 43% of type 1 diabetes patients are middle-aged (40-64 years old)
    .

    This item of data reminds us that for type 1 diabetes, the clinical focus cannot be limited to children/adolescents
    .

    The richer the country, the higher the incidence of type 1 diabetes? The study found that the estimated number of people with type 1 diabetes in 2017 was 234,710 (Table 1)
    .

    Although high-income countries (HICs) account for only 17% of the global population, the incidence of type 1 diabetes is as high as 49%.
    The reasons behind this need to be analyzed in depth
    .

    Note: LAC, Latin America and the Caribbean; NA, North America Figure 1 Age distribution of new type 1 diabetes patients Table 1 Type 1 diabetes incidence/prevalence Note: LAC, Latin America and the Caribbean; NA, North America
    .

    In 2017, there were more than 9 million type 1 diabetes patients in the world, with the highest prevalence rate in North America and the lowest in Asia.
    In 2017, the total number of patients with type 1 diabetes in the world is estimated to be 9,004,610 (Table 1), and the age is mainly concentrated in the middle-aged population between 40-64 years old.
    ➤0-14 age group: 6%; ➤15-39 age group: 35%; ➤40-64 age group: 43%; ➤≥65 age group: 16 %
    .

    Figure 2 The age distribution of existing type 1 diabetes patients (2017) In addition, although high-income countries (HICs) account for only 17% of the global population, the proportion of patients with type 1 diabetes is as high as 52%, with upper middle income Countries (UMICs), low-middle-income countries (LMICs) and low-income countries (LIC) accounted for 19%, 27%, and 2%, respectively
    .

    After standardizing age, the prevalence of type 1 diabetes in high-income countries, upper-middle-income countries, low-middle-income countries, and low-income countries are 3.
    27/1000, 1.
    77/1000, 0.
    57/1000, and 0.
    28/1000, respectively
    .

    Divided by country/region: After age standardization, the highest prevalence of type 1 diabetes is North America (4.
    4/1000), followed by Oceania (3.
    4/1000) and Europe (3.
    0/1000), and the lowest is Africa (0.
    8 /1000) and Asia (0.
    6/1000)
    .

    The focus of type 1 diabetes should not be limited to children/adolescents.
    The author pointed out that in contrast to the rapid increase in the number of type 2 diabetes, type 1 diabetes, which accounts for a relatively small proportion, is difficult to attract people's attention (this study estimates that there are about 9 million 1 Type-type diabetes patients, accounting for about 2% of the total cases of diabetes), but the loss of life span caused by the latter also requires attention
    .

    Although the clinic attaches great importance to the diagnosis and treatment of type 1 diabetes in children/adolescents, studies have found that up to 43% of patients are actually concentrated in the 40-64 age group.
    "Does the attention need to be redistributed?" Maybe It is also a question that needs to be considered in the clinic
    .

    In addition, there are huge differences in the incidence and prevalence of type 1 diabetes between different countries/regions and income levels
    .

    The prevalence of type 1 diabetes in high-income countries is approximately 10 times that of low-income countries
    .

    The age-standardized prevalence rate is highest in North America (4.
    4/1000) and lowest in Asia (0.
    6/1000)
    .

    According to WHO, IDF and the results of this study, the proportion of type 1 diabetes in different populations varies greatly
    .

    For example, type 1 diabetes in China accounts for less than 1% of all diabetes, while in the United Kingdom and Finland, the proportions reach 8.
    6% and 17%
    .

    In short, this study may help different countries to formulate medical and health care measures according to local conditions to better meet the needs of patients with type 1 diabetes at all stages of their life course
    .

    Yimaitong compiled and compiled from: Green, A.
    ,Hede,SM,Patterson,CC et al.
    Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults.
    Diabetologia (2021).
    https://doi .
    org/10.
    1007/s00125-021-05571-8
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.